Markets

BridgeBio Pharma’s acoramidis demonstrated a 44% reduction in cardiovascular mortality risk in ATTR-CM patients after 42 months in the ATTRibute-CM open label extension study. The study also showed a 46% hazard reduction in cardiovascular mortality or first cardiovascular hospitalization. Approximately 50% of participants exhibited disease stabilization compared to less than 20% on placebo at month 30. Acoramidis, marketed as Attruby® and BEYONTTRA®, exhibited the fastest benefit observed in a Phase 3 ATTR-CM study, with positive changes seen in 3 months.

BYD reported record first-half 2025 revenue of ¥371.3 billion, surpassing Tesla for the first time. The company emphasized strengthening industry collaboration through proactive coordination, optimizing payment terms, and fostering a mutually beneficial ecosystem for stakeholders. BYD highlighted its already low DPO and further reductions compared to 2024, prioritizing prompt supplier payments. This follows a commitment by BYD and other Chinese automakers to limit payment terms to 60 days, addressing concerns about supply chain pressures and promoting sustainable industry growth.

Cytokinetics’ MAPLE-HCM trial results show aficamten significantly outperformed metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten improved exercise capacity (+1.1 mL/kg/min), while metoprolol decreased it (-1.2 mL/kg/min). 51% of aficamten patients improved in functional class, compared to 26% on metoprolol. Aficamten also showed superiority in secondary endpoints. The FDA is reviewing aficamten with a PDUFA date of December 26, 2025. A higher incidence of hypertension was noted with aficamten.

Gold Reserve Ltd.’s subsidiary, Dalinar Energy, lost the auction for PDV Holding, Inc. (CITGO’s parent company) to Amber Energy Inc., despite a higher revised bid of $7.9 billion. Gold Reserve plans to challenge the decision, citing grounds for objection after Amber Energy’s winning bid of $5.9 billion. Dalinar Energy claims its bid offered superior economic value, including debt financing and consideration for junior creditors. An objection deadline is set for September 6, 2025, followed by a hearing on September 15, 2025.

Saba Capital Income & Opportunities Fund II (SABA) announced the breakdown of its August 29th distribution of $0.058 per share. As of August 22nd, 36.14% is net investment income and 63.86% is return of capital. Fiscal year-to-date, 42.50% is net investment income, and 57.50% is return of capital. SABA cautions against drawing conclusions from distribution figures, as a significant portion is return of capital. The fund targets a $0.058/share monthly distribution, but this is subject to change. Investors should review SEC filings for risk factors.

MSP Recovery, Inc. (NASDAQ: MSPR) announced a non-binding term sheet for a secured term loan facility of up to $55 million to bolster working capital and growth. The facility is divided into two tranches and secured by a first-priority lien. Warrants issued to the lender, could represent roughly 46.0% of MSP Recovery’s fully diluted equity if fully drawn. The deal includes potential for the investor to acquire additional claim rights, and lender oversight, including a possible Chief Restructuring Officer appointment. Certain aspects are subject to shareholder approval.

Tulla Resources Group will acquire the remaining shares of THEMAC Resources Group for $0.08 per share, an 11% premium. Tulla, already holding 60.39% of THEMAC, needs shareholder (2/3 majority) and minority shareholder approval at an October 7, 2025 meeting. Key shareholders (18.64%) support the deal, expected to close mid-to-late October 2025. The board, backed by a fairness opinion, unanimously approved the arrangement. Upon completion, THEMAC will be delisted.

Exelixis, Inc. announced the promotion of Dana T. Aftab, Ph.D., to Executive Vice President, Research and Development. Aftab, with 25 years at Exelixis, will lead drug discovery, translational research, product development, and medical affairs. She played a critical role in developing CABOMETYX® (cabozantinib). The company aims to maximize its portfolio, including zanzalintinib. Amy Peterson, M.D., previously Executive Vice President, Product Development & Medical Affairs, has left Exelixis. Exelixis is focused on creating next-generation oncology medicines.

VCI Global (VCIG) launched its CyberSecure Cloud service in Malaysia, a military-grade encrypted data protection platform. The EAL4-certified service uses proprietary QuantVault technology and offers scalable storage (3TB-50TB) with automated backup and firewall. It targets Malaysia’s growing cybersecurity market, projected to reach US$700M by 2030. Expansion is planned for Singapore, Hong Kong, Dubai, and Indonesia, with a customer portal launching by September 2025. This aims to capture a significant share of the expanding ASEAN cybersecurity market, estimated to reach US$12.2B by 2030.

Since AlphaGo’s victory, AI has permeated diverse aspects of life, from medical diagnostics to robotics. Embodied AI faces data scarcity and algorithmic limits, addressed by solutions like Nvidia’s Omniverse and Baidu AI Cloud’s data expertise. Baidu AI Cloud, a leader in AI public cloud, offers full-stack development tools like Qianfan and Baige, enabling innovations in robotics and gaming (NetEase Fuxi’s *Justice Mobile*). AIGC benefits from Baidu’s heterogeneous computing platform. The “cloud-intelligence integration” approach enables developers to focus on AI application refinement, mirroring the role of utilities in the Industrial Revolution.